Biological properties of the angiotensin peptides other than angiotensin II: Implications for hypertension and cardiovascular diseases

Journal of Hypertension

Volumn 20, Issue 5, 2002, Pages 793-799

  Cesari, Maurizio ^a   Rossi, Gian Paolo ^a   Pessina, Achille Cesare ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Angiotensin fragments; Cardiovascular disease; Hypertension

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-8]; ANGIOTENSIN[2-8]; ANGIOTENSIN[3-8]; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; DEGRADATION; HOMEOSTASIS; HUMAN; HUMAN TISSUE; HYPERTENSION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0036563250     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200205000-00002     Document Type: Review

References (73)

1. Niere und kreislauf
2. Local renin-angiotensin systems
3. Angiotensin II type 2 receptor mediates programmed cell death
4. An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: Measurement of eight angiotensin peptides in human plasma
5. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: Predominant role of angiotensin III in the control of vasopressin release
6. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses
7. Aminopeptidase A antiserum inhibits intracerebroventricular angiotensin II-induced dipsogenic and pressor responses
8. Aminopeptidase A inhibitors as potential central antihypertensive agents
9. Des-Asp1-angiotensin I: A metabolite of angiotensin I in the perfused feline adrenal
10. Angiotensin III: (des-aspartic acid-1)-angiotensin II. Evidence and speculation for its role as an important agonist in the renin-angiotensin system
11. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor
12. Characterization of a binding site for angiotensin IV on bovine aortic endothelial cells
13. Important role for angiotensin III and IV in the brain renin-angiotensin system
14. Evidence for angiotensin IV receptors in human collecting duct cells
15. Structure-binding studies of the adrenal AT4 receptor: Analysis of position two- and threemodified angiotensin IV analogs
16. AT4 receptors: Specificity and distribution
17. Elucidation of a specific binding site for angiotensin 11(3-8), angiotensin IV, in mammalian heart membranes
18. Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation
19. A specific binding site for angiotensin II(3-8), angiotensin IV, in rabbit cardiac fibroblasts
20. Stimulation of DNA and RNA synthesis in cultured rabbit cardiac fibroblasts by angiotensin IV
21. Up regulation of AT4 receptor levels in carotid arteries following balloon injury
22. Autoradiographic identification of kidney angiotensin IV binding sites and angiotensin IV-induced renal cortical blood flow changes in rats
23. Angiotensin IV AT4-receptor system in the rat kidney
24. Renal hemodynamic responses to intrarenal infusion of ligands for the putative angiotensin IV receptor in anesthetized rats
25. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis
26. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function
27. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin
28. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV
29. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
30. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure
31. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans
32. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women
33. Converting enzyme determines plasma clearance of angiotensin-(1-7)
34. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme
35. N-Domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: Angiotensin-(1-7) and keto-ACE
36. Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells
37. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor
38. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide
39. Interaction of bradykinin and angiotensin-(1-7) in the central modulation of the baroreflex control of the heart rate
40. Interactions between angiotensin-(1-7), kinins, and angiotensin II in kidney and blood vessels
41. Differential actions of angiotensin-(1-7) in the kidney
42. 2 release
43. Intrarenal de novo production of angiotensin I in subjects with renal artery stenosis
44. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects
45. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: Implications for a novel angiotensin receptor
46. Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo
47. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide
48. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide
49. Counterregulatory actions of angiotensin-(1-7)
50. Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system
51. Potentiation of the hypotensive effect of bradykinin by angiotensin-(1-7)-related peptides
52. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats
53. Cardiovascular effects of angiotensin-(1-7) in conscious spontaneously hypertensive rats
54. Alterations in prostaglandin production in spontaneously hypertensive rat smooth muscle cells
55. Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor
56. Biological activities of angiotensin II-(1-6)-hexapeptide and angiotensin II-(1-7)-heptapeptide in man
57. Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm
58. Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats
59. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension
60. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan
61. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system
62. Characterization of angiotensin receptors on human skin fibroblasts
63. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth
64. Opposing actions of angiotensins on angiogenesis
65. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury
66. State-of-the-art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle
67. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline
68. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme
69. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active
70. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides
71. Angiotensin I converting enzyme and its role in neuropeptide metabolism
72. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors
73. Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme